



Supramolecular attack particles (SMAPs) for pancreatic cancer immunotherapy

Michael Dustin, Shivan Sivakumar, Oskar Stauffer, Ashwin Jainarayanan, Vineethkrishna Chandrasekar, Benedikt Kessler, Eric O'Neill, Matthew Wood, Enas Abu Shah (new address-Adaptimmune), Stefan Balint (new address-ONI), Cosima Baldari (Siena), Shiladitya Sengupta (Boston), Tanmoy Saha (Boston)

University of Oxford, University of Siena, Harvard Medical School

Characterising the Pancreatic Cancer Microenvironment




Type 2 and 3, believed to be same phenotype, Difference can be explained by cellularity

STATUS OF T-CELLS IN PANCREATIC CANCER by MASS CYTOMETRY

Majority of CD8 and CD4 are senescent



tSNE reveals TIGIT is highly expressed in tregs with some expression of CD8 effector and NK cells

Tregs have significant TIGIT, ICOS, CD39 and CTLA4 expression




Supramolecular attack particles (SMAPs)

- Natural glycoprotein shell-cytotoxic core nanoparticles discovered in Dustin lab (patent/publication 2020).
- Combines the key cytotoxic agents from CTL in a 110 nm particle that can kill target cells autonomously.
- T cells deliver SMAPs to tumors, but this process fails in PDAC.
- We propose to directly target SMAPs to tumors through the blood and circumvent PDAC defences.



SMAP biology and composition




- Supramolecular attack particle

- Glycoprotein shell

- Thrombospondin-1 (gray)
 - Thrombospondin-4
 - Galectin-1
 - Others components- proteomics

- Cytotoxic core


- Granzyme B (blue)
 - Granzyme A
 - Perforin-1 (green)
 - Interferon gamma
 - Chemokines
 - Serglycin (red)




Balint et al, *Science* 2020
Chang et al, *Nature Comms* 2022
50% of degranulation events release SMAPs.
50% of GZMB and 100% of THBS1 is in SMAPs.

Proteomics by Benedikt Kessler (Oxford).

PDAC expresses high levels of thrombospondins 1 and 4, part of SMAP shell.



smart-SMAP1



- SMAPs are cytotoxic particles generated by cytotoxic T cells (50% of GZMB).
- Pancreatic cancer cell lines produce SMAP-like particles containing same form of THBS1.
- We propose to develop Smart-SMAP – CAR-like cytotoxic particles to target pancreatic cancer.

Acknowledgements

Lab team:

Jesusa Capera Aragonés- IL2 (Cue)

Sooraj Achar- NIH OXCAM (Altan-Bonnet)

Daniel Beckers- ToIDC (RACE II)

Pablo Cespedes- BMS- Signal 4

Vineeth Chandrasekar- SMAPCAN

Lina Chen- protein infrastructure

Ewoud Compeer- ATTACK- Treg SMAPs

Hannah Dada- NIH OXCAM (Altan-Bonnet)

Ashwin Jainarayanan- SYNECT/ATTACK

Elke Kurz- SMAPCAN

Alex Leithner- CD44 (Schrodinger)

Olga Margaritaki- SMAPs (Diamond)

Alex Mørch- RIFINs and Coreceptors

Shivan Sivakumar- BMS- PANCAN

Oskar Stauer (Marie Curie)- Synthetic cells

Salvatore Valvo- bilayer infrastructure

Recent Alumni

James Felce (ONI)- Chemokine Receptors

Viveka Mayya (Century)- T cell search

Philippos Demetriou (Cyprus)- CD2 corolla

David Depoil (Evotech)- CD2 corolla

Enas Abu Shah (Adaptimmune)- T cell eng.

Stefan Balint- (ONI)- SMAPs

Audun Kvalvaag (Oslo)- Clathrin dynamics

<http://www.ibiology.org/ibioseminars/michael-dustin-part-1.html>

Maria Harkiolaki



Rachael Bashford-Rogers

Roman Fischer

Benedikt Kessler

Matthew Higgins

Tom Harrison

Hisashi Arase

Marco Fritzsche

Ahmed Ahmed



Catharien Hilkens

Elliot Philips

Xiangpeng Kong



Jens Rettig

Hsin-Fang Chang

Cosima Baldari

Salvatore Valitutti

Chiara Romagnani

Timo Rückert

